ResMed's Recent Share Price Pullback and Growth Expectations: A Valuation Check

ResMed (RMD) stock has recently experienced a 0.6% decline, with a 12.8% decline over the past 30 days and a 7.7% decline year-to-date. Despite this, the company's fair value is estimated at $296.87, which is an intrinsic discount of 18.3% and a gap of 31.4% to the analyst price target. The most followed narrative suggests that ResMed is undervalued due to its strong recurring revenue streams, innovative product development, and competitive differentiation. However, the company's future growth is dependent on maintaining pricing power and addressing potential risks from competitors.